Clinical trials: malaria
Malaria, Falciparum
Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults
The primary objective is to evaluate the safety of 3 doses given at D0, W4, and W26 of 50 µg dosage of AMA1-DiCo adjuvanted either with GLA-SE or Alhydrogel® in healthy European adults not previously exposed to the parasite…
- Trial name
- AMA1-DiCo (NCT02014727)
- Testing
- Group A1 : 50µg AMA1-DiCo + Alhydrogel, Group A2 : 50 µg AMA1-DiCo+ GLA-SE
- Where
- 2 sites in Burkina Faso, France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Malaria
L9LS in Women of Childbearing Potential in Mali
Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Women of Childbearing Potential (WOCBP) in Mali
- Trial name
- NCT07060508
- Testing
- Single dose of 1800 mg L9LS SC
- Where
- 3 sites in Mali
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Plasmodium Falciparum Malaria
Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar
The primary objective of the study was to determine PCR corrected cure-rates up to day 42 in children with uncomplicated malaria, treated with either Artesunate + Amodiaquine or Coartem®.
- Trial name
- AcoI (NCT03764527)
- Testing
- Artemether-lumefantrine, Coadministered Artesunate plus Amodiaquine
- Volunteers
- 408 people
- Sponsor
- Professor Anders Björkman
Malaria, Stillbirths
The Impact of Sulphadoxine-Pyrimethamine Use At Scale on Newborn Outcomes in Nigeria
The purpose of this study is to test the feasibility of the scale-up of sulphadoxine- pyrimethamine (SP) for the preventive treatment of malaria in pregnancy in three Local Government Areas (LGAs) in Sokoto State, Nigeria.
- Trial name
- MIPP-NG (NCT02758353)
- Testing
- Community distribution of SP
- Volunteers
- 31,493 people, healthy volunteers welcome
- Sponsor
- JSI Research & Training Institute, Inc.
Plasmodium Falciparum
ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
Elimination of P. falciparum (PF) malaria across a territory requires universal access to treatment of clinical cases for communities, and specific targeting of places or population groups where malaria transmission persists in…
- Trial name
- ELISA (NCT03132402)
- Testing
- ELISA validation
- Where
- Thailand
- Volunteers
- 1,656 people
- Sponsor
- University of Oxford
Malaria
Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children
The purpose of this study is to assess the safety and immunogenicity of the candidate malaria vaccine in HIV-infected infants and children
- Trial name
- NCT01148459
- Testing
- GSK Biological's Investigational Malaria Vaccine 257049, Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);, Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).
- Where
- 2 sites in Kenya
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Febrile Illness Acute, Biomarkers
Clinical Aspects, Management and Surveillance of Febrile Illnesses in DRC
The epidemiology and outcome of febrile illnesses in the Democratic Republic of Congo (DRC) is poorly documented. The FIKI² study, a prospective observational study of community-acquired febrile illnesses coordinated by ITM and…
- Conditions
- Febrile Illness Acute, Biomarkers, Surveillance
- Trial name
- FI-CARE (NCT07345286)
- Where
- Democratic Republic of the Congo
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Fever
Comparative Efficacy of Single-dose Doxycycline Versus Standard 5- Day Amoxicillin Treatment
Abstract: Background The current practice in Senegal is to use broad-spectrum antibiotics including amoxicillin and/or cotrimoxazole in case of non-malarial fevers. First-line treatment with doxycycline has cured such patients.
- Trial name
- NCT03765931
- Testing
- Doxycycline, Amoxicillin
- Where
- Senegal
- Volunteers
- 274 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Pharmacokinetics of Tafenoquine
Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07052162
- Testing
- Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat
- Where
- Papua New Guinea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Curtin University
Malaria in Pregnancy
Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy
Malaria is a major contributor of disease burden in Sub-Saharan Africa, and pregnant women and children are the most vulnerable population.
- Trial name
- NCT00711906
- Testing
- Cotrimoxazole, Sulfadoxine-pyrimethamine
- Where
- 2 sites in Zambia
- Volunteers
- 352 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria, PLASMODIUM FALCIPARUM MALARIA
Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT)
The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda.
- Trial name
- AVERT (NCT07749911)
- Testing
- R21/Matris-M Malaria vaccine
- Where
- 21 sites in Burkina Faso, Uganda
- Volunteers
- 20,000 people
- Sponsor
- Clinton Health Access Initiative Inc.
Malaria, Falciparum
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
- Trial name
- NCT07646353
- Testing
- GSK4425689A SC, GSK4425689A IV
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Anemia
Evaluation of a Comprehensive School Health Programme in Zambia
In Zambia, the health and well-being of children aged 5 to 14 has often been overlooked, leading to various health challenges affecting their development and education.
- Conditions
- Malaria, Anemia, Diarrhea
- Trial name
- NCT06560853
- Testing
- Comprehensive School Health Programme, Deworming and vitamin A supplementation delivery
- Where
- 6 sites in Zambia
- Volunteers
- 28,700 people, healthy volunteers welcome
- Sponsor
- London School of Economics and Political Science
Malaria
Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults
The study is designed to establish the best dose to safely infect healthy individuals with Plasmodium falciparum sporozoites (PfSPZ) via intravenous (IV) injection.
- Trial name
- NCT01624961
- Testing
- PfSPZ Challenge
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Pregnancy, Malaria
Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya
Malaria in pregnancy (MiP) due to Plasmodium falciparum infection is a major cause of maternal morbidity and poor birth outcomes.
- Trial name
- STOP MiP KENYA (NCT01669941)
- Testing
- IPTp-SP, IPTp-DP, ISTp-DP
- Where
- 4 sites in Kenya
- Volunteers
- 1,546 people
- Sponsor
- Kenya Medical Research Institute
Plasmodium Falciparum Malaria
Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
The primary trial objective is to determine the clinically effective dose of orally administered pyronaridine/artesunate (Pyramax®, PA) with a 3:1 ratio to treat adults with acute, symptomatic, uncomplicated P.
- Trial name
- NCT01594931
- Testing
- pyronaridine/artesunate
- Where
- 6 sites in Cambodia, Indonesia and 4 more
- Volunteers
- 477 people
- Sponsor
- Medicines for Malaria Venture
Malaria, Malnutrition, Child
Assessment of a Combined Strategy of SMC + Nutrients Supplementation to Tackle Malaria and Malnutrition
Malaria and malnutrition represent major public health concerns worldwide especially in Sub-Sahara Africa. Despite implementation of Seasonal Malaria Chemoprophylaxis (SMC), an intervention aimed at reducing malaria prevalence…
- Trial name
- SMC-NUT (NCT04238845)
- Testing
- AQSP Administration, Supplementation with Plumpy'Doz, Supplementation with Vitamin A
- Where
- Burkina Faso
- Volunteers
- 1,059 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche en Sciences de la Sante, Burkina Faso
Malaria
Prenatal Iron and Malaria Study
The purpose of this study is to compare the presence of Plasmodium infection in parturient women who antenatally received a combination of iron-fortified foods with iron supplements versus iron-fortified foods only.
- Trial name
- PIMAL (NCT01308112)
- Testing
- iron
- Where
- Kenya
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
Resistance to antimalarial drugs represents a major obstacle for controlling malaria in endemic countries, so that most sub-Saharan countries have changed their antimalarial drug policy to the new Artemisinin Containing…
- Trial name
- NCT00808951
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- Burkina Faso
- Volunteers
- 440 people
- Sponsor
- Centre Muraz
Malaria
A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate
This is an open-label, multi-centre Phase I/IIa dose escalation blood-stage malaria CHMI trial to assess the safety, immunogenicity and efficacy of the candidate malaria vaccine RH5.1/AS01.
- Trial name
- NCT02927145
- Testing
- RH5.1/ ASO1
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- University of Oxford
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.